Edition:
United States

Bioporto A/S (BIOPOR.CO)

BIOPOR.CO on Copenhagen Stock Exchange

2.39DKK
29 Jul 2016
Change (% chg)

kr.-0.03 (-1.24%)
Prev Close
kr.2.42
Open
kr.2.43
Day's High
kr.2.43
Day's Low
kr.2.37
Volume
180,387
Avg. Vol
733,287
52-wk High
kr.5.40
52-wk Low
kr.1.40

BIOPOR.CO

Chart for BIOPOR.CO

About

Bioporto A/S is a Denmark-based company engaged in the development and marketing of in vitro diagnostic (IVD) assays. The Company’s portfolio comprises five product categories: The Neutrophil gelatinase-associated lipocalin (NGAL) Test, which is a test for diagnosing acute kidney injury; NGAL Enzyme-linked immunosorbent assay... (more)
No analyst recommendations are available for BIOPOR.CO.

Overall

Beta: 0.50
Market Cap(Mil.): kr.309.74
Shares Outstanding(Mil.): 129.60
Dividend: --
Yield (%): --

Financials

  BIOPOR.CO Industry Sector
P/E (TTM): -- 38.77 39.28
EPS (TTM): -0.08 -- --
ROI: -36.91 15.17 14.40
ROE: -36.99 16.12 15.47

BRIEF-BioPorto to reapply for FDA approval of NGAL Test

* Financial outlook for 2016 is maintained Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Jul 04 2016

BRIEF-Bioporto: FDA rejects application for registration of NGAL Test

* The FDA rejects application for the registration og The NGAL Test

May 30 2016

BRIEF-Bioporto NGAL Forms patent upheld after EPO ruling

* Says the company's NGAL Forms patent is upheld after European Patent Office (EPO) ruling

May 18 2016

BRIEF-Bioporto Q1 EBIT widens to loss DKK 5.4 million

* Q1 revenue of 5.2 million Danish crowns ($803,101.21) compared to 4.1 million crowns in year-earlier period, corresponding to a growth of 26 percent

May 04 2016

BRIEF-BioPorto cuts 2016 EBIT outlook due to warrants program

* Adjusts EBIT forecast for 2016 due to warrants program for employees

Apr 08 2016

BRIEF-BioPorto EBIT loss narrows to DKK 12.8 mln

* FY revenues up 9 pct to 20.4 million Danish crowns ($3.03 million)

Mar 16 2016

Earnings vs. Estimates

No consensus analysis data available.

Analyst Research Reports

Report Title Price
Provider : Reuters Investment Profile
$20.00
Provider : Wright Reports
$75.00
Provider : GlobalData
$75.00
Provider : GlobalData
$50.00
Provider : GlobalData
$125.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.